Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
复制标题
DOI：
10.1111/apt.15689
复制
发表时间：
2020-04-01
影响因子：
7.6
通讯作者：
Pierik, Marieke J.
中科院分区：
文献类型：
--
作者：
Biemans, Vince B. C.;Sleutjes, Jasmijn A. M.;Pierik, Marieke J.
背景托法替尼是一种Janus激酶抑制剂，被批准用于治疗溃疡性结肠炎（UC）。目的评价托法替尼的有效性、安全性和在日常实践中的应用。无皮质类固醇临床缓解（短期临床结肠炎活动指数[SCCAI]）
Background Tofacitinib is a Janus kinase inhibitor approved for the treatment of ulcerative colitis (UC).Aim To evaluate effectiveness, safety and use of tofacitinib in daily practice.Methods UC patients initiating tofacitinib were prospectively enrolled in 15 hospitals in the Netherlands. Corticosteroid-free clinical remission (short clinical colitis activity index [SCCAI]